Apigenin alleviates the symptoms of Staphylococcus aureus pneumonia by inhibiting the production of alpha-hemolysin

FEMS Microbiology Letters

Volumn 338, Issue 2, 2013, Pages 124-131

  Dong, Jing ^a   Qiu, Jiazhang ^a   Wang, Jianfeng ^a   Li, Hongen ^a   Dai, Xiaohan ^a   Zhang, Yu ^a   Wang, Xin ^a   Tan, Wei ^a   Niu, Xiaodi ^a   Deng, Xuming ^a   Zhao, Shuhua ^b  

^a JILIN UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

hemolysin; Apigenin; Pneumonia; Staphylococcus aureus

Indexed keywords

ALPHA HEMOLYSIN; APIGENIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL PROTECTION; COCULTURE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; SYMPTOM; TOXIN SYNTHESIS;

ANIMALS; APIGENIN; BACTERIAL TOXINS; HEMOLYSIN PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); PETROSELINUM CRISPUM; STAPHYLOCOCCUS AUREUS;

EID: 84871712999     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/1574-6968.12040     Document Type: Article

References (31)

1. Bubeck Wardenburg J, Patel RJ & Schneewind O (2007a) Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 75: 1040-1044.
2. Cegelski L, Marshall GR, Eldridge GR & Hultgren SJ (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6: 17-27.
3. Clinical and Laboratory Standards Institute (2005) Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI/NCCLS document M100-S15. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA.
4. Diep BA, Carleton HA, Chang RF, Sensabaugh GF & Perdreau-Remington F (2006) Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 193: 1495-1503.
5. Duthie G & Crozier A (2000) Plant-derived phenolic antioxidants. Curr Opin Clin Nutr Metab Care 3: 447-451.
6. Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3: 948-958.
7. Francis JS, Doherty MC, Lopatin U et al. (2005) Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40: 100-107.
8. Gomez MI, Lee A, Reddy B, Muir A, Soong G, Pitt A, Cheung A & Prince A (2004) Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 10: 842-848.
9. Hirst RA, Yesilkaya H, Clitheroe E, Rutman A, Dufty N, Mitchell TJ, O'Callaghan C & Andrew PW (2002) Sensitivities of human monocytes and epithelial cells to pneumolysin are different. Infect Immun 70: 1017-1022.
10. Kernodle DS, McGraw PA, Barg NL, Menzies BE, Voladri RK & Harshman S (1995) Growth of Staphylococcus aureus with nafcillin in vitro induces alpha-toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis 172: 410-419.
11. Klevens RM, Morrison MA, Nadle J et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771.
12. Koomanachai P, Crandon JL, Banevicius MA, Peng L & Nicolau DP (2009) Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 53: 5060-5063.
13. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
14. Leng BF, Qiu JZ, Dai XH et al. (2011) Allicin reduces the production of alpha-toxin by Staphylococcus aureus. Molecules 16: 7958-7968.
15. Liang X, Yan M & Ji Y (2009) The H35A mutated alpha-toxin interferes with cytotoxicity of staphylococcal alpha-toxin. Infect Immun 77: 977-983.
16. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F & Etienne J (1999) Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29: 1128-1132.
17. Liu LZ, Fang J, Zhou Q, Hu X, Shi X & Jiang BH (2005) Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol 68: 635-643.
18. Locksley RM, Cohen ML, Quinn TC, Tompkins LS, Coyle MB, Kirihara JM & Counts GW (1982) Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection. Ann Intern Med 97: 317-324.
19. Mandell LA, Wunderink RG, Anzueto A et al. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2): S27-S72.
20. McElroy MC, Harty HR, Hosford GE, Boylan GM, Pittet JF & Foster TJ (1999) Alpha-toxin damages the air-blood barrier of the lung in a rat model of Staphylococcus aureus-induced pneumonia. Infect Immun 67: 5541-5544.
21. McElroy MC, Cain DJ, Tyrrell C, Foster TJ & Haslett C (2002) Increased virulence of a fibronectin-binding protein mutant of Staphylococcus aureus in a rat model of pneumonia. Infect Immun 70: 3865-3873.
22. Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M & Rubens CE (1996) Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells. Infect Immun 64: 3818-3826.
23. Novick RP (2003) Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 48: 1429-1449.
24. Patel AH, Nowlan P, Weavers ED & Foster T (1987) Virulence of protein A-deficient and alpha-toxin-deficient mutants of Staphylococcus aureus isolated by allele replacement. Infect Immun 55: 3103-3110.
25. Qiu J, Feng H, Lu J, Xiang H, Wang D, Dong J, Wang J, Wang X, Liu J & Deng X (2010a) Eugenol reduces the expression of virulence-related exoproteins in Staphylococcus aureus. Appl Environ Microbiol 76: 5846-5851.
26. Qiu J, Jiang Y, Xia L, Xiang H, Feng H, Pu S, Huang N, Yu L & Deng X (2010b) Subinhibitory concentrations of licochalcone A decrease alpha-toxin production in both methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Lett Appl Microbiol 50: 223-229.
27. Rasko DA & Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9: 117-128.
28. Rubinstein E, Cammarata S, Oliphant T & Wunderink R (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32: 402-412.
29. Worlitzsch D, Kaygin H, Steinhuber A, Dalhoff A, Botzenhart K & Doring G (2001) Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother 45: 196-202.
30. Xiong YQ, Willard J, Yeaman MR, Cheung AL & Bayer AS (2006) Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental infective endocarditis. J Infect Dis 194: 1267-1275.
31. Yoon MS, Lee JS, Choi BM et al. (2006) Apigenin inhibits immunostimulatory function of dendritic cells: implication of immunotherapeutic adjuvant. Mol Pharmacol 70: 1033-1044.